Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADME study of balovaptan in healthy men
NCT02179866Phase 1Completed
- Sponsor
- Roche
- Start
- Jun 2014
- Primary completion
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of balovaptan in Autism Spectrum Disorder (ASD), sponsored by Roche. Primary endpoints: Total recovery of radioactivity over time in urine and feces expressed as a percentage of the total radioactive dose administered and Pharmacokinetic profile of total drug-related material, RO5285119 and its metabolites, as appropriate in plasma, estimated Cmax. Started Jun 2014; status: completed.
02
Drugs
balovaptan
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT02179866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02179866.